Fig. 1.
Evolution of CRP levels and fevers after anti–IL-6 antibody treatment.
Asterisks indicate patients in whom the absence of CRP level normalization on day 3 led to a 2-fold increase in the anti–IL-6 treatment dose.
Evolution of CRP levels and fevers after anti–IL-6 antibody treatment.
Asterisks indicate patients in whom the absence of CRP level normalization on day 3 led to a 2-fold increase in the anti–IL-6 treatment dose.
